A breakthrough finding offers hope for people at genetic risk of heart failure: the diabetes drug dapagliflozin reduced hospitalization risk by approximately 80% in patients carrying cardiomyopathy-associated genetic variants.

The research highlights how precision medicine is transforming treatment approaches, allowing doctors to identify which patients will benefit most from existing medications. This discovery could mean fewer hospital visits and better quality of life for thousands of genetically vulnerable individuals who face elevated heart failure risk. Read the full story →

Today's takeaway: Understanding your genetic profile could unlock access to life-changing treatments you didn't know could help you.